01
Understand the Alzheimer’s continuum and MCI
There has been a conceptual shift in how Alzheimer’s disease is defined. Alzheimer’s disease is now considered to form a continuum, encompassing pathologic changes without clinical symptoms (preclinical AD), mild cognitive impairment (MCI) due to AD and AD dementia.1–3
More than 800,000 Australians
aged 50 years and over were estimated to have MCI in 20184
Approximately 8 in 10 people
with amnestic MCI go on to develop Alzheimer’s disease within 7 years5
‘We now realise that dementia is only the end part of the story of Alzheimer’s.’
A/Prof Michael Woodward
Discover more
MCI ON THE ALZHEIMER’S CONTINUUM
Our understanding of MCI is changing as clinical research pushes the threshold for diagnosis earlier in the disease continuum. Prof Philip Morris AM and A/Prof Michael Woodward discuss current clinical challenges on the MindChangers podcast.
Login Required
THE SYDNEY MEMORY AND AGEING STUDY
Prof Henry Brodaty discusses mild cognitive impairment and key findings from one of Australia’s largest and longest running studies of ageing and cognitive health.
Login Required
THE STAGES OF ALZHEIMER’S DISEASE
An overview of international definitions for MCI and the Alzheimer’s continuum. How has our definition changed due to advances in biomarkers and a deeper understanding of pathological changes?
Login Required
DELINEATING THE CAUSE OF MEMORY IMPAIRMENT
An expert panel discusses a patient case study which highlights the Alzheimer’s continuum as well as the challenges of detecting early cognitive change at the 6th Congress of the European Academy of Neurology (EAN) 2020.
Login Required
‘There are many types of mild cognitive impairment…it’s a good concept and it guides the clinician – but it’s indicative rather than definitive.’
Prof Henry Brodaty
References: 1. Dubois B et al. Alzheimers Dement. 2016;12(3):292–323. 2. Alzheimer’s Association. Diagnostic criteria and guidelines. Available at: www.alz.org/research/for_researchers/diagnostic-criteria-guidelines (Accessed January 2021). 3. Sperling RA et al. Alzheimers Dement. 2011;7(3):280–92. 4. Baxi SM et al. Assessing the preparedness of the Australian health care system infrastructure for an Alzheimer’s disease-modifying therapy. Available at: www.rand.org/pubs/research_reports/RR2891.html (Accessed January 2021). 5. National Institute on Aging. (2017). Symptoms and diagnosis of Alzheimer’s disease: What is mild cognitive impairment? Available at: www.nia.nih.gov/health/what-mildcognitiveimpairment(Accessed January 2021).
Holder Header navigation - CSS
Pilar page - 1 column - background card component - CSS
Pilar page - 1 column - reference section - CSS
Pilar page - 2 column - image, text, cta - CSS
Pilar page - AddThis - CSS
HTML container